ENERGEAP KID

Glavne informacije

  • Zaščiteno ime:
  • EnergeaP kid pločevinka 1000 g
  • Farmacevtska oblika:
  • prašek za peroralno suspenzijo
  • Enote v paketu:
  • pločevinka 1000 g
  • Uporabi za:
  • ljudje
  • Vrsta medicine:
  • Alopatska drog

Dokumentov

Lokalizacija

  • Na voljo v:
  • EnergeaP kid pločevinka 1000 g
    Slovenija
  • Jezik:
  • slovenščina

Terapevtski podatki

  • Terapevtska skupina:
  • Hranila za otroke

Drugi podatki

Stanje

  • Source:
  • JAZMP - Javna agencija RS za zdravila in medicinske pripomočke - Slovenia Medicines Agency
  • Status dovoljenje:
  • Živilo
  • Zadnja posodobitev:
  • 18-01-2018

Podatki za bolnike: sestava, indikacije, neželeni učinki, odmerjanje, interakcij, nosečnost, dojenje

Energea

je praškasta tekoča hrana, še posebej

primerna za prehransko uravnavanje povezanih bolezni

energetske podhranjenosti pri otrocih.

Energea

je lahko topen koncentrat hranil, primer-

na za izključno hranjenje ali tudi za dodatno hranjenje.

Lastnosti izdelka

Razmerje

hranil

beljakovine:

ogljikovi

hidrati:

maščobe

10:35:55 energijskih %.

Energea

vsebuje mlečne

beljakovine z visoko biološko vrednostjo. Linolna in

-lino-

lenska kislina (

) so prisotne v optimalnem razmerju.

Energea

nizka vsebnost laktoze

je brez fruktoze in vlaknin, brez glutena

je lahko topna v vodi, pijačah, juhah in pirejih

je skoraj nevtralnega okusa - primerna za dopol-

nitev sladkih in slanih jedi in za testo

ima nizko osmotski učinek zaradi uporabe mal-

todekstrina

Doziranje

Dnevno dozo

Energea

je treba določiti v načrtu

prehrane,

upoštevajoč

individualne

zahteve

hranil

otroka. Dnevno dozo porazdelimo na več posamez-

nih obrokov.

- Izključno hranjenje

za pokrivanje dnevnih zahtev vseh bistvenih hranilnih

snovi, otroci od

1 - 3 leta je potrebno 230 g (m) / 210 g (ž)

Energea

4 - 6 let, je potrebno 310 g (m) / 290 g (ž)

Energea

7 - 9 let, je potrebno 400 g (m) / 350 g (ž)

Energea

- Dodatno hranjenje

Odmerek je potrebno določiti v skladu z otro-

kovimi osebnimi zahtevami.

Uporaba

Dodajte 10 - 20 g

Energea

na 100 - 150

ml pitne vode in dobro premešajte. Uporabite

mikser, če je na voljo.

Energea

lahko

enostavno

dodate

zmešate v sladkih in slanih živilih in pijačah, kot

so juhe in vse vrste pirejev.

Vedno pripravite

Energea

sveže.

Priložena,

napolnjena

poravnana

žlička

vsebuje

približno 10 g

Energea

Kid.

Pomembno obvestilo! Samo za uporabo pod zdravniškim nadzorom! Primerno za uporabo kot edini vir

prehrane ali za dodatno hranjenje. Ne uporabljajte v primeru alergij na kravje beljakovine in pri motnjah ab-

sorpcije in prebave. Vsebuje lahko prebavljive ogljikove hidrate. V primeru motenj glukozne tolerance upo-

rabljajte le pod skrbnim nadzorom presnove. EnergeaP Kid se ne sme uporabljati, če je enteralno hranjenje

kontraindicirano ali v primerih preobčutljivosti ali alergije na eno od vsebovanih sestavin. Primeren je za otroke

od 1 do 10 let starosti. Ni za parenteralno uporabo.

14/10/15 d14/07/18

Za otroke od 1 do 10 leta starosti

Energea

P

Kid

Serviervorschläge

Dietetično živilo za posebne zdravstvene namene

za dietetsko uravnavanje podhranjenosti,

katere vzrok so različne bolezni

nizka vsebnost laktoze

lahko topno

prehransko

uravnoteženo

praškasta

tekoča hrana

PREHRANKSA VREDNOST

Energea

P Kid

100 g

prahu

20 g

1 obrok

energija

2092

kcal

maščobe

od tega nasičene

enkrat nenasičene

večkrat nenasičene

ogljikovi hidrati

od tega sladkorji

prehranske vlaknine

beljakovine

sol

0,12

vitamini

vitamin A

vitamin D

vitamin E

vitamin K1

Vitamin C

tiamin (vit. B1)

0,06

riboflavin (vit. B2)

0,08

niacin

vitamin B6

0,04

folna kislina

vitamin B12

biotin

pantotenska kislina

minerali

kalij

klorid

kalcij

fosfor

magnezij

elementi v sledovih

železo

cink

baker

0,24

0,05

mangan

florid

0,34

0,07

selen

krom

molibden

PODROBNEJŠE PREHRANSKE INFORMACIJE

laktoza

0,04

fruktoza

linolna kislina

-linolenska kislina

natrij

OSMOLALNOST

mosmol

pitne

vode,

damo

Energea

na 150 ml vode

mosmol

pitne

vode,

damo

Energea

na 100 ml vode

SESTAVINE

Maltodekstrin,

mlečnih

beljakovin,

posneto mleko

, rastlinska olja (repično olje, koruz-

no olje, palmovo olje, sončnično olje), vitamin B2,

vitamin B1, magnezijev karbonat, emulgator:

sojin

lecitin

& E 472c, kalijev karbonat, kalcijev fosfat, že-

lezov sulfat, natrijev klorid , vitamin C, cinkov sulfat,

vitamin E, natrijev florid, vitamin D, niacin, manganov

sulfat, pantotenska kislina, bakrov sulfat, vitamin B6,

vitamin A, folna kislina, kromov (III) klorid, natrijev

selenit, kalijev jodid, natrijev molibdat, vitamin K, bi-

otin, vitamin B12.

OPOMBA Pločevinko vedno takoj po uporabi do-

bro zaprite s pokrovom. Po odprtju porabite vse-

bino v 4 tednih.

SHRANJEVANJE Shranjujte v hladnem in suhem

prostoru.

1000 g

UPORABNO NAJMANJ DO

Datum odtisnjen na dnu pločevinke

Dietetično živilo za posebne zdravstvene namene za dietetsko uravnavanje bolezni poveza-

nih s podhranjenosto, primeren za izključno ali dopolnilno hranjenje. Za otroke od 1 do 10

leta starosti.

predlog priprave

Distribucija v Sloveniji

MagPharm d.o.o.

Dunajska cesta 181, 1000 Ljubljana

GSM 040 457 767

zdravkoplecnik.zdravko@gmail.com

metaX Institut für Diätetik GmbH

Am Strassbach 5

61169 Friedberg/Germany

www.metax.org

4 *wgpqjf#yx-,,x*

3-12-2018

FDA Alerts Pet Owners about Potentially Toxic Levels of Vitamin D in Several Dry Pet Foods

FDA Alerts Pet Owners about Potentially Toxic Levels of Vitamin D in Several Dry Pet Foods

The FDA is investigating the presence of elevated, potentially toxic levels of vitamin D in several dry pet foodsVitamin D in very high amounts can cause serious health problems like kidney failure or death.

FDA - U.S. Food and Drug Administration

29-11-2018

FDA warns company for selling e-liquids that resemble kid-friendly foods as part of the agency’s ongoing Youth Tobacco Prevention Plan

FDA warns company for selling e-liquids that resemble kid-friendly foods as part of the agency’s ongoing Youth Tobacco Prevention Plan

FDA issued a warning letter to Electric Lotus LLC for selling nicotine-containing e-liquids used in e-cigarettes with labeling and/or advertising that cause them to resemble kid-friendly food products.

FDA - U.S. Food and Drug Administration

27-11-2018

When to Give Kids Medicine for Coughs and Colds

When to Give Kids Medicine for Coughs and Colds

Sometimes a cold is just a cold. What can worried parents do when their babies and young children have a cold or cough? The FDA has some advice and tips.

FDA - U.S. Food and Drug Administration

30-10-2018

Mountain Warehouse Limited recalls BPA-Free Printed Kids' Water Bottles

Mountain Warehouse Limited recalls BPA-Free Printed Kids' Water Bottles

If the spout of the water bottle becomes detached during use, a small ring can be exposed and both the spout and the ring may pose a choking hazard.

Health Canada

19-9-2018

Exclusive Brands and iSweet recall Kidsmania Bubble Dozer

Exclusive Brands and iSweet recall Kidsmania Bubble Dozer

Health Canada's sampling and evaluation program has determined that these products do not meet the Canadian safety requirements for toys.Small parts can break off the toys, posing a choking hazard to young children.

Health Canada

18-9-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on launch of ‘The Real Cost’ Youth E-Cigarette Prevention Campaign amid evidence of sharply rising use among kids

Statement from FDA Commissioner Scott Gottlieb, M.D., on launch of ‘The Real Cost’ Youth E-Cigarette Prevention Campaign amid evidence of sharply rising use among kids

Statement from FDA Commissioner Scott Gottlieb, M.D., on launch of ‘The Real Cost’ Youth E-Cigarette Prevention Campaign amid evidence of sharply rising use among kids.

FDA - U.S. Food and Drug Administration

18-9-2018

FDA launches new, comprehensive campaign to warn kids about the dangers of e-cigarette use as part of agency’s Youth Tobacco Prevention Plan, amid evidence of sharply rising use among kids

FDA launches new, comprehensive campaign to warn kids about the dangers of e-cigarette use as part of agency’s Youth Tobacco Prevention Plan, amid evidence of sharply rising use among kids

FDA launched new, comprehensive campaign to warn kids about the dangers of e-cigarette use as part of agency’s Youth Tobacco Prevention Plan, amid evidence of sharply rising use among kids.

FDA - U.S. Food and Drug Administration

23-8-2018

Companies cease sales of e-liquids with labeling or advertising that resembled kid-friendly foods following FDA, FTC warnings

Companies cease sales of e-liquids with labeling or advertising that resembled kid-friendly foods following FDA, FTC warnings

FDA announced that all 17 manufacturers, distributors, and retailers that were warned in May have stopped selling the e-liquids used in e-cigarettes with labeling or advertising resembling kid-friendly food products.

FDA - U.S. Food and Drug Administration

22-8-2018

King Bio Issues Voluntary Nationwide Recall of It’s Kids and Infant Products Due to Potential Microbial Contamination

King Bio Issues Voluntary Nationwide Recall of It’s Kids and Infant Products Due to Potential Microbial Contamination

King Bio is voluntarily recalling the below products to the consumer level. A small percentage of our products produced between 08/01/2017 and 04/2018 have tested positive for microbial contamination. Out of an abundance of caution, we are recalling the products and lot numbers below

FDA - U.S. Food and Drug Administration

14-8-2018

Calikids Inc. recalls children's jackets with waist drawstrings

Calikids Inc. recalls children's jackets with waist drawstrings

Drawstrings on children’s outerwear can become entangled or caught on playground slides, hand rails, school bus doors or other moving objects, posing a significant entanglement hazard to children.

Health Canada

16-5-2018

FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings

FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings

FDA is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) concerning gadolinium remaining in patients’ bodies, including the brain, for months to years after receiving these drugs. Gadolinium retention has not been directly linked to adverse health effects in patients with normal kidney function, and we have concluded that the benefit of all approved GBCAs continues to outweigh any potential risks.

FDA - U.S. Food and Drug Administration

10-5-2018

FDA warns more companies to stop misleading kids with e-liquids that resemble kid-friendly foods as part of Youth Tobacco Prevention Plan

FDA warns more companies to stop misleading kids with e-liquids that resemble kid-friendly foods as part of Youth Tobacco Prevention Plan

FDA warns more companies to stop misleading kids with e-liquids that resemble kid-friendly foods as part of Youth Tobacco Prevention Plan

FDA - U.S. Food and Drug Administration

1-5-2018

FDA, FTC take action against companies misleading kids with e-liquids that resemble children’s juice boxes, candies and cookies

FDA, FTC take action against companies misleading kids with e-liquids that resemble children’s juice boxes, candies and cookies

FDA, FTC take action against companies misleading kids with e-liquids that resemble children’s juice boxes, candies and cookies

FDA - U.S. Food and Drug Administration

25-4-2018

Lamictal (lamotrigine): Drug Safety Communication - Serious Immune System Reaction

Lamictal (lamotrigine): Drug Safety Communication - Serious Immune System Reaction

The FDA is warning that the medicine lamotrigine (Lamictal) for seizures and bipolar disorder can cause a rare but very serious reaction that excessively activates the body’s infection-fighting immune system. This can cause severe inflammation throughout the body and lead to hospitalization and death, especially if the reaction is not diagnosed and treated quickly. As a result, we are requiring a new warning about this risk be added to the prescribing information in the lamotrigine drug labels. The immun...

FDA - U.S. Food and Drug Administration

25-9-2018

We hope this extra time will allow stakeholders to continue to provide  input on the ideas shared during the two-day Pediatric Device  Development public meeting held last month. #devices4kids https://go.usa.gov/xPjwd 

We hope this extra time will allow stakeholders to continue to provide input on the ideas shared during the two-day Pediatric Device Development public meeting held last month. #devices4kids https://go.usa.gov/xPjwd 

We hope this extra time will allow stakeholders to continue to provide input on the ideas shared during the two-day Pediatric Device Development public meeting held last month. #devices4kids https://go.usa.gov/xPjwd 

FDA - U.S. Food and Drug Administration

14-8-2018

We are excited by all the feedback we received over the last two days during the Pediatric Medical Device Development meeting. All presentation materials will be available on the Pediatric Medical Device webpage at  https://go.usa.gov/xUF39   #Devices4Kid

We are excited by all the feedback we received over the last two days during the Pediatric Medical Device Development meeting. All presentation materials will be available on the Pediatric Medical Device webpage at https://go.usa.gov/xUF39  #Devices4Kid

We are excited by all the feedback we received over the last two days during the Pediatric Medical Device Development meeting. All presentation materials will be available on the Pediatric Medical Device webpage at https://go.usa.gov/xUF39  #Devices4Kids #MedicalDevice pic.twitter.com/XGwlpgopGn

FDA - U.S. Food and Drug Administration

14-8-2018

Today is Day 2 of the Pediatric Medical Device Public Meeting. Today we will be discussing the importance of International Regulation Harmonization.  https://go.usa.gov/xU6rg  #Devices4Kids #MedicalDevicepic.twitter.com/bMYgjX8CTX

Today is Day 2 of the Pediatric Medical Device Public Meeting. Today we will be discussing the importance of International Regulation Harmonization. https://go.usa.gov/xU6rg  #Devices4Kids #MedicalDevicepic.twitter.com/bMYgjX8CTX

Today is Day 2 of the Pediatric Medical Device Public Meeting. Today we will be discussing the importance of International Regulation Harmonization. https://go.usa.gov/xU6rg  #Devices4Kids #MedicalDevice pic.twitter.com/bMYgjX8CTX

FDA - U.S. Food and Drug Administration

14-8-2018

We thank the participants that joined in person and remotely during Day 1 of the Pediatric Medical Device Development public meeting.  We look forward to continuing discussions around increasing medical device options for children today.  #Devices4Kids #M

We thank the participants that joined in person and remotely during Day 1 of the Pediatric Medical Device Development public meeting. We look forward to continuing discussions around increasing medical device options for children today. #Devices4Kids #M

We thank the participants that joined in person and remotely during Day 1 of the Pediatric Medical Device Development public meeting. We look forward to continuing discussions around increasing medical device options for children today. #Devices4Kids #MedicalDevice pic.twitter.com/7cXPFfvfif

FDA - U.S. Food and Drug Administration

14-8-2018

FDA Commissioner, @SGottliebFDA , speaking during day 1 of the Pediatric Medical Device Development Public Meeting  #devices4kids #FDA #MedicalDevicepic.twitter.com/0I1Poe9Yqn

FDA Commissioner, @SGottliebFDA , speaking during day 1 of the Pediatric Medical Device Development Public Meeting #devices4kids #FDA #MedicalDevicepic.twitter.com/0I1Poe9Yqn

FDA Commissioner, @SGottliebFDA , speaking during day 1 of the Pediatric Medical Device Development Public Meeting #devices4kids #FDA #MedicalDevice pic.twitter.com/0I1Poe9Yqn

FDA - U.S. Food and Drug Administration

13-8-2018

More highlights from today's Pediatric Medical Device Development Public Meeting: Dr. Michelle Tarver of CDRH highlighting that collaboration is imperative in helping to promote pediatric device development. #devices4kids #MedicalDevicepic.twitter.com/mzl

More highlights from today's Pediatric Medical Device Development Public Meeting: Dr. Michelle Tarver of CDRH highlighting that collaboration is imperative in helping to promote pediatric device development. #devices4kids #MedicalDevicepic.twitter.com/mzl

More highlights from today's Pediatric Medical Device Development Public Meeting: Dr. Michelle Tarver of CDRH highlighting that collaboration is imperative in helping to promote pediatric device development. #devices4kids #MedicalDevice pic.twitter.com/mzlmU6Nq9U

FDA - U.S. Food and Drug Administration

13-8-2018

Highlights from today's Pediatric Medical Device Development Public Meeting: Bakul Patel discussed #digitalhealth and how technology enables development and access to safe medical devices #devices4kids #FDAPreCertpic.twitter.com/X4wQbX0Tjc

Highlights from today's Pediatric Medical Device Development Public Meeting: Bakul Patel discussed #digitalhealth and how technology enables development and access to safe medical devices #devices4kids #FDAPreCertpic.twitter.com/X4wQbX0Tjc

Highlights from today's Pediatric Medical Device Development Public Meeting: Bakul Patel discussed #digitalhealth and how technology enables development and access to safe medical devices #devices4kids #FDAPreCert pic.twitter.com/X4wQbX0Tjc

FDA - U.S. Food and Drug Administration

13-8-2018

Today is Day 1 of the Pediatric Medical Device Development Public Meeting. Today we will discuss the programs, policies, and procedures at the #FDA intended to streamline evidence generation.  https://go.usa.gov/xU6rg 
#devices4kids #Pediatricspic.twitter

Today is Day 1 of the Pediatric Medical Device Development Public Meeting. Today we will discuss the programs, policies, and procedures at the #FDA intended to streamline evidence generation. https://go.usa.gov/xU6rg  #devices4kids #Pediatricspic.twitter

Today is Day 1 of the Pediatric Medical Device Development Public Meeting. Today we will discuss the programs, policies, and procedures at the #FDA intended to streamline evidence generation. https://go.usa.gov/xU6rg  #devices4kids #Pediatrics pic.twitter.com/3tXTgwPJPo

FDA - U.S. Food and Drug Administration

9-7-2018

Scientific guideline:  Concept paper on the need to develop a reflection paper on development of medicinal products to prevent and treat acute kidney injury, draft: consultation open

Scientific guideline: Concept paper on the need to develop a reflection paper on development of medicinal products to prevent and treat acute kidney injury, draft: consultation open

The concept paper will include discussion of and recommendations for the requirements for evaluation and development of medicinal products for the prevention and/or treatment of acute kidney injury (AKI) and its long-term complications. Relevant topics for discussion include patient populations, endpoints, study methodology, and study duration.

Europe - EMA - European Medicines Agency